Hovione, an international integrated pharmaceutical development and manufacturing organization, and Firstgene Life Sciences, a portfolio company of the Swiss incubator Xlife Sciences AG, have entered a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene. Under the terms of the collaboration, Hovione will grant Firstgene an exclusive lice...